论文部分内容阅读
血管扩张剂被广泛地用于心力衰竭的治疗,它对抗心衰时血管的过度收缩,可能的生理效益包括血流和血容量的合理分配,但对血管的精确效应有待阐明。由于血管扩张,使前负荷和后负荷降低,进而改善心脏功能,但血管在心功减退时的作用尚不十分清楚。临床上的效益包括呼吸困难的减轻、组织代谢的改善和运动耐量的增加(慢性心力衰竭患者)。血管扩张剂治疗心衰的最初十年积累了丰富的临床资料,包括可能的效益、药物的适宜剂量和类型;第二个十年,重要的问题是最后肯定这些药物在心衰的应
Vasodilators are widely used in the treatment of heart failure. They oppose the excessive contraction of blood vessels during heart failure. The possible physiological benefits include the rational distribution of blood flow and blood volume, but the precise effect on blood vessels needs to be elucidated. Due to vasodilation, the preload and postload reduce, thereby improving cardiac function, but the role of blood vessels in cardiac dysfunction is not yet clear. Clinical benefits include relief of dyspnea, improved tissue metabolism, and increased exercise tolerance (chronic heart failure patients). The first decade of vasodilators in the treatment of heart failure has accumulated a wealth of clinical information, including possible benefits, appropriate doses and types of drugs; the second decade, the important issue is to conclude that these drugs in the heart failure should